key: cord-0944090-p3wh7aok
authors: Di Giacomo, Anna Maria; Giacobini, Gianluca; Anichini, Gabriele; Gandolfo, Claudia; D’alonzo, Vincenzo; Calabrò, Luana; Lofiego, Maria Fortunata; Cusi, Maria Grazia; Maio, Michele
title: SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines
date: 2022-05-25
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2022.05.018
sha: 6cf8a7488aecac6535ffe4d3107c0bb68f07bde7
doc_id: 944090
cord_uid: p3wh7aok

INTRODUCTION: The protective role against SARS-CoV-2 infection by the third booster dose of mRNA vaccines in cancer patients with solid malignancies is remains a highly challenging issue. We prospectively investigated the occurrence of COVID-19 in cancer patients on active therapy after they had received the booster vaccine dose. METHODS: Cancer patients on treatment at the Center for Immuno-Oncology (CIO) of the University Hospital of Siena, Italy, and health care workers at CIO who had received a booster third dose of mRNA vaccine entered a systematic follow-up monitoring period by nasopharyngeal swabs to prospectively assess their potential risk of SARS-CoV-2 infection. Serological and microneutralization assay were utilized to assess levels of anti-spike IgG, and of neutralizing antibodies to the SARS-CoV-2 Wild Type, Delta and Omicron variants, respectively, after the booster dose and after negativization of the nasopharyngeal swab for those who had developed COVID-19. RESULTS: Ninety cancer patients with solid tumors on active treatment (Cohort 1) and 30 health care workers (Cohort 2) underwent a booster third dose of mRNA vaccine. After the booster dose, the median value of anti-spike IgG was higher (p = 0.009) in patients than in healthy subjects. Remarkably, 11/90 (12%) patients and 11/30 (37%) healthy subjects tested positive to SARS-CoV-2 infection during the monitoring period. Similar levels of anti-spike IgG and of neutralizing antibodies against all the investigated variants, with geometric mean titers of neutralizing antibodies against the Omicron being the lowest were detected after the booster dose and after COVID-19 in infected subjects from both Cohorts. The time-to-negativization of the nasopharyngeal swabs was similar in cancer patients and healthy subjects, and COVID-19 related symptoms were mainly mild in both Cohorts. CONCLUSIONS: The occurrence of SARS-CoV-2 infection we observed in a sizable proportion of booster-dosed cancer patients and in healthy subjects during the Omicron outbreak indicates that highly specific vaccines against SARS-CoV-2 variants are urgently required.

Since the very beginning of the SARS-Cov-2 pandemic oncologists paid great attention to the potential interference of COVID-19 on the clinical course of the disease (1) and on ongoing therapies in cancer patients (2) . Major concerns were raised by immunecheckpoint (ICI) therapy, due to its ability to boost patients' immune response (3) , and to the potential radiologic overlaps between ICI-and COVID-19-induced pneumonitis (4) . In the absence of specific guidelines, the initial reports of patients who successfully resumed ICI therapy after COVID-19 were encouraging (5) . In that uncertain scenario, the swift availability of mRNA vaccines to SARS-COV-2 raised the additional question about their immunologic efficacy in cancer patients, particularly in those on active anti-neoplastic therapy. Thus, vaccination campaigns of cancer patients were complemented by a number of studies demonstrating the ability of mRNA vaccines to progressively induce and boost the titers of circulating anti-spike IgG and of neutralizing antibodies, along with subsequent mRNA vaccine doses (6) (7) ; nevertheless, seroconversion seemed to be impaired by patients' performance status (8) . On our hand, investigating a longitudinally-followed group of 131 cancer patients with solid tumors on active therapy, we found similar anti-spike IgG titers in patients and in a control group of 42 vaccinated health care workers after the second dose of mRNA vaccine; of note, median values of anti-spike IgG were significantly higher in patients undergoing immune checkpoint(s) (ICI) therapy, as compared to those receiving chemo-or targeted-therapy plus ICI (9) .

The mandated booster vaccination with mRNA vaccines mRNA-1273 (Moderna) and BNT162b2 (Pfizer) was shown to significantly increase the titer of neutralizing antibodies to SARS-CoV-2 wild type (WT) and Delta variants, and to a lesser extent to the recently J o u r n a l P r e -p r o o f 4 emerged Omicron variant, both in cancer patients on active therapy (10) and in healthy subjects, compared to the second dose (11) (12) . A protective role of a third mRNA vaccine dose against SARS-CoV-2 infection was initially reported in healthy volunteers before the outbreak of the Omicron variant (13); however, a further vaccination showed low efficacy in preventing SARS-CoV-2 infection during the outburst of the Omicron variant (14) . In this scenario, the protective role against SARS-CoV-2 infection of the third booster vaccination in cancer patients on active therapy is highly relevant and remained to be assessed (10), along with the debated suitability for a fourth dose with available mRNA vaccines in these highly fragile patients.

We now report the efficacy of the booster mRNA vaccine dose in preventing SARS-CoV-2 infection in cancer patients with solid malignancies on active therapy.

Cancer patients on active therapy at the Center for Immuno-Oncology (CIO) at the University Hospital of Siena, Italy, and health care workers at CIO underwent a booster third dose of mRNA vaccine. After this booster dose all subjects entered a systematic follow-up monitoring period to prospectively assess their potential risk of SARS-CoV-2 infection. As per institutional guidelines, patients and healthy subjects tested negative to nasopharyngeal swabs within 48 h prior to hospital admissions and every 10 days, respectively. Sera were collected from blood drawings from routine workup after the booster dose and after the This assay was performed on an Abbott Alinity (Abbott Diagnostics) according to the manufacturer's instructions. A sample was considered positive when the result was >50.0 AU/ml. Values higher than 40,000 AU/ml were not further investigated and reported as 40,000, being the upper limit of the kit detection. All data are represented as median with two-sided 95% CI estimated using a normal approximation. Statistical significance for differences between cancer patients and healthy controls was carried out using nonparametric two-sided Mann-Whitney test.

Titers of neutralizing antibodies to SARS-CoV-2 WT, Delta and Omicron variants in cancer patients and healthy subjects were carried out by microneutralization assay on Vero 

Ninety cancer patients (Cohort 1) on active treatment and 30 health care workers (Cohort 2) (Table S1) The median time-to-negativization of the nasopharyngeal swabs did not significantly differ between cancer patients and healthy subjects (Table 1) , and COVID-19 related symptoms were mild in the majority of subjects in both Cohorts (Table 1) , with no investigated subjects requiring hospitalization or dead due to COVID-19 (data not shown).

The worldwide outburst of the highly-infective SARS-CoV-2 Omicron variant in December 2021 (16) 

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Challenges in lung cancer therapy during the COVID-19 pandemic

SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome

Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy -a single centre prospective study

Seropositivity and Neutralising Antibodies at Six Months after BNT162b2 Vaccination in Patients with Solid Tumors Eur J Cancer

Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment

Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix

COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera

Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel

4th Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC. medRxiv preprint doi

COVID-19 Treatment Guidelines. National Institutes of Health

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study

Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection. Front Immunol

Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis

Response to mRNA vaccination for COVIDamong patients with multiple myeloma

Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events -a retrospective cohort study

Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article

Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose!

Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer

Omicron variant: A clear and present danger for patients with cancer

Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron

Highlights • Patients with solid tumors on active therapy received a third dose of mRNA vaccine to SARS-CoV-2

Anti-spike and neutralizing Ig equally increased in patients and healthy subjects

• COVID-19 risk was prospectively assessed during Omicron outbreak

High rates of COVID-19 occurred in booster-dosed patients and healthy subjects

• More specific vaccines to SARS-CoV-2 variants are urgently required

Merck Sharp Dohme, and Sanofi and has received compensated educational activities from Bristol Myers Squibb, Merck Sharp Dohme, Pierre Fabre and Sanofi; LC served as an advisor to Bristol-Myers Squibb, and received compensated educational activities from Bristol-Myers Squibb and Astra Zeneca; MM has served as a consultant and/or advisor to Roche